-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Breast cancer (International Classification of Diseases, 10th Revision [ICD-10] codes C50.0–50.9) is a malignant tumor that originates in the breast tissue. Breast cancer cells begin inside the milk ducts of the breast. The earliest form (in situ) is not life-threatening and can be detected in early stages. The most common type of non-invasive (stage 0) types of breast cancer is called ductal carcinoma in situ (DCIS) (American Cancer Society, 2022; World Health Organization, 2024). DCIS refers to abnormal cells that...
-
Product Insights
NewChronic Lymphocytic Leukemia (CLL) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Chronic Lymphocytic Leukemia (CLL) - Global Clinical Trials Review, 2024" provides an overview of Chronic Lymphocytic Leukemia (CLL) Clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Mycosis Fungoides - Global Clinical Trials Review, 2024" provides an overview of Mycosis Fungoides Clinical trials scenario. This report provides top line data relating to the clinical trials on Mycosis Fungoides. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Ewing Sarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Ewing Sarcoma Clinical Trial Report Overview A total of 434 Ewing Sarcoma clinical trials were conducted as of February 2024. The Ewing Sarcoma clinical trial report provides a comprehensive understanding of the Ewing Sarcoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · ...
-
Product Insights
Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glioblastoma Multiforme (GBM) Clinical Trial Report Overview A total of 2,375 Glioblastoma Multiforme (GBM) clinical trials were conducted as of February 2024. The GBM clinical trial report provides a comprehensive understanding of the GBM clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The HER2- breast cancer clinical trial report provides a comprehensive understanding of the human epidermal growth factor receptor 2 negative breast cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the...
-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · ...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Antibody drug conjugates(ADC) cancer therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian...